BridgeBio Pharma, Inc.(BBIO)

Description: BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.

---

Keywords: Organ Systems Clinical Development Protein Kinase Inhibitor Tyrosine Kinase Tyrosine Kinase Receptors Amyloidosis Amyloid Hyperplasia Cardiomyopathy Fibroblast Growth Factor Receptor Myopathy Transthyretin Polyneuropathy Congenital Adrenal Hyperplasia TTR Amyloidosis Achondroplasia Familial Amyloid Polyneuropathy

---

Home Page: www.bridgebio.com

BBIO Technical Analysis

421 Kipling Street
Palo Alto, CA 94301
United States
Phone: 650 391 9740

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)